Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing ...
Piper Sandler lowered the firm’s price target on Sage Therapeutics (SAGE) to $9 from $26 and keeps an Overweight rating on the shares following ...
Discover how Sage and GoCardless streamline payments for SMBs, reducing admin, saving costs, improving cash flow and boosting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results